申请人:——
公开号:US20030105135A1
公开(公告)日:2003-06-05
The invention concerns phenoxypropanolamines of formula (I) wherein: R
1
represents a hydrogen, a —S(O)
z
—(C
1
-C
4
)Alk-R′ group, R′ being H, phenyl or (C
1
-C
4
) alkoxy), —NHSO
2
—(C
1
-C
4
) Alk, NHCO(C
1
-C
4
) Alk; m and n are each independently 0, 1 or 2; R
2
and R
3
represent independently a hydrogen, a (C
5
-C
6
) alkyl, (C
3
-C
6
) cycloalkyl, (C
1
-C
4
) alkoxy, hydroxy(C
1
-C
4
)alkyl, (C
1
-C
4
) alkoxy-(C
1
-C
4
)alkyl, mono-or di-(C
1
-C
4
)Alk-amino(C
1
-C
4
)alkyl, pyrrolidino-(C
1
-C
4
)alkyl, phenylamino, (C
2
-C
4
)alkenyl group, or an aromatic or heteroaromatic group substituted or not with a group R
4
; R
2
and R
3
can also together constitute a saturated or unsaturated cycle of 3 to 6 atoms capable of bearing a (C
1
-C
4
) alkyl, amino(C
1
-C
4
)alkyl, carbamoyl or benzyl substituent; R
4
represents a hydrogen or a halogen, a —CO(C
1
-C
4
)Alk group or a —NHSO
2
—(C
1
-C
4
)Alk group; a (C
1
-C
4
)Alk group, a (C
1
-C
4
)alkoxy group, a halogen, —COOH, —COO(C
1
-C
4
)Alk, —CN, —CONR
3
R
4
, —NO
2
, —SO
2
NH
2
, —NHSO
2
(C
1
-C
4
)Alk; z is 1 or 2; and their salts and solvates. Said compounds have an agonist activity with respect to &bgr;-3 adrenergic receptors.
该发明涉及化合物(I),其中:R1代表氢,—S(O)z—(C1-C4)Alk-R′基团,其中R′为H、苯基或(C1-C4)烷氧基,—NHSO2—(C1-C4)Alk,NHCO(C1-C4)Alk;m和n各自独立地为0、1或2;R2和R3分别独立地代表氢、(C5-C6)烷基、(C3-C6)环烷基、(C1-C4)烷氧基、羟基(C1-C4)烷基、(C1-C4)烷氧基-(C1-C4)烷基、单或双-(C1-C4)Alk-氨基(C1-C4)烷基、吡咯烷基-(C1-C4)烷基、苯基氨基、(C2-C4)烯基基团,或被取代或未取代的芳香或杂芳基团,该基团取代或未取代有一个R4基团;R2和R3还可以共同构成3到6个原子的饱和或不饱和环,能够承载(C1-C4)烷基、氨基(C1-C4)烷基、氨基甲酰基或苄基取代基;R4代表氢或卤素,—CO(C1-C4)Alk基团或—NHSO2—(C1-C4)Alk基团;(C1-C4)Alk基团、(C1-C4)烷氧基、卤素、—COOH、—COO(C1-C4)Alk、—CN、—CONR3R4、—NO2、—SO2NH2、—NHSO2(C1-C4)Alk;z为1或2;以及它们的盐和溶剂化合物。这些化合物对β-3肾上腺素能受体具有激动剂活性。